FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS

	As of June 30, 2021				Fair Value Measurements
	Carrying		Fair		As of June 30, 2021
	Amount		Value		Level 1		Level 2		Level 3
					(unaudited)
Liabilities:
Contingent consideration:
Asuragen (1)	$	2,175	$	2,175	$	-	$	-	$	2,175
Other long-term liabilities:
Warrant liability (2)		230		230		-		-		230
	$	2,405	$	2,405	$	-	$	-	$	2,405

	As of December 31, 2020				Fair Value Measurements
	Carrying		Fair		As of December 31, 2020
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen (1)	$	2,216	$	2,216	$	-	$	-	$	2,216
Other long-term liabilities:
Warrant liability (2)		21		21		-		-		21
	$	2,237	$	2,237	$	-	$	-	$	2,237

⁽¹⁾⁽²⁾ See Note 9, Accrued Expenses and Long-Term Liabilities

SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION

Certain of the Company’s non-financial assets, such as other intangible assets and goodwill, are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

								Cancellation		Adjustment to Fair
								of Obligation/		Value/
	December 31, 2020		Payments			Accretion		Conversions Exercises		Mark to Market			June 30, 2021
	(unaudited)
Asuragen	$	2,216	$	(254	)	$	270	$	-	$	(57	)	$	2,175
Underwriters Warrants		21		-			-		-		209			230
	$	2,237	$	(254	)	$	270	$	-	$	152		$	2,405